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The objective of this study was to determine if experimental infection of neonatal calves with Mycobacterium
avium subsp. paratuberculosis would invoke changes in the percentages of total B cells in the peripheral blood
mononuclear cell population and of subpopulations of B cells as determined by CD5, CD25, and CD45RO
markers during a 12-month period. Experimental infection groups included control (noninfected), oral (in-
fected with M. avium subsp. paratuberculosis strain K-10), oral/DXM (pretreatment with dexamethasone before
oral inoculation), i.p. (intraperitoneal inoculation), and oral/M (oral inoculation with mucosal scrapings from
a cow with clinical disease) groups. Over the course of the study, the percentages of total B cells in nonstimu-
lated and antigen-stimulated cell cultures increased for oral and i.p. group calves, with the highest percentages
noted at 3 and 6 months. Oral/M group calves had increased percentages of activated B cells, as determined
by CD5dim and CD5bright markers, at 9 and 12 months. Experimental infection by all methods resulted in
increased expression of CD25 and CD45RO B cells early in the study, but the most significant results were
observed at 12 months for oral/DXM and oral/M group calves. Immunoblot analyses with a whole-cell sonicate
of M. avium subsp. paratuberculosis demonstrated the most reactivity with sera from i.p. group calves and the
least reactivity with sera from oral group calves. Further evidence of M. avium subsp. paratuberculosis-specific
antibody responses in the i.p. group calves was demonstrated using the ethanol vortex enzyme-linked immu-
nosorbent assay (EvELISA) method. In summary, an induction of B cell responses was noted after experi-
mental infection with M. avium subsp. paratuberculosis, with differences in responses noted according to the
method of experimental inoculation.
Similar to the majority of mycobacterial diseases, paratuber-
culosis (Johne’s disease) is controlled primarily by T cell re-
sponses following infection with Mycobacterium avium subsp.
paratuberculosis. Little is known about the role that B cells may
play in the immune responses to M. avium subsp. paratubercu-
losis infection, yet it is widely accepted that antibodies secreted
by B cells provide little benefit to the host in controlling or
clearing the infection (17). However, B cells also present cog-
nate antigen to CD4 T cells and secrete cytokines and, as
such, play a significant role in maintaining the full complement
of immunity necessary to control intracellular infections (14).
A loss of cell-mediated immunity dominated by CD4 T cells
has been observed in the later stages of M. avium subsp. para-
tuberculosis infection and is concomitant with increasing num-
bers of B cells and an increase in humoral immune responses
(16, 20). Yet little work has been done to define B cell re-
sponses or to elucidate B cell subpopulations during M. avium
subsp. paratuberculosis infection.
There are several markers for B cells that are indicative of
activation, such as CD5, CD25, and CD45. CD5 is a membrane
glycoprotein that is expressed on T cells as well as B-1a lym-
phocytes (4). CD5 is recognized as a mediator of T cell-B cell
interactions, and increased expression of this cell surface
marker has been noted on B cells in autoimmune diseases such
as systemic lupus erythematosus, rheumatoid arthritis, and in-
flammatory bowel disease (13, 15, 21). Likewise, CD25 expres-
sion increases upon activation of B cells, and this activation has
been associated with increased antigen presentation by cells (6,
9). The CD45 marker is associated with the memory phenotype
when it is expressed on CD4 T cells (CD4 CD45RO), but
it has also been demonstrated for B cell populations, suggest-
ing that a memory B cell phenotype is present (14). In human
patients with inflammatory bowel diseases such as Crohn’s
disease and ulcerative colitis, the CD45 marker on B cells can
be used as an indicator of the stage of disease (23). Expression
of CD45RO on CD19 B cells in the lamina propria and the
peripheral blood was indicative of patients transitioning to
more advanced stages of disease (23).
Previous observations have demonstrated that the stage of
paratuberculosis has a significant impact on the number and
phenotype of circulating B cells in cattle that are naturally
infected with M. avium subsp. paratuberculosis (18). We pro-
posed to further evaluate the expression of B cell markers in
concordance with the appearance of M. avium subsp. paratu-
berculosis-specific antibody in calves experimentally infected
with live M. avium subsp. paratuberculosis. In a previous pub-
lication, we demonstrated that the route of experimental inoc-
ulation with M. avium subsp. paratuberculosis (oral versus in-
traperitoneal [i.p.]) and the strain of M. avium subsp.
paratuberculosis used for inoculation (laboratory strain versus
clinical isolate) impacted the degree of tissue colonization in a
12-month study (19). Calves inoculated orally with a clinical
* Corresponding author. Mailing address: USDA-ARS, National
Animal Disease Center, 1920 Dayton Ave., Building 20, Ames, IA
50010. Phone: (515) 337-7304. Fax: (515) 337-7428. E-mail: judy.stabel
@ars.usda.gov.
 Published ahead of print on 4 May 2011.
1139
isolate of M. avium subsp. paratuberculosis had the largest
number of positive tissue sites (15/22 sites), whereas calves in
the i.p. group had the smallest number (8.5/22 sites). Here we
present further observations on the impact of oral or i.p. in-
oculation and bacterial strain on the temporal changes in ac-
tivated B cell subpopulations.
MATERIALS AND METHODS
Animals and experimental infection. As previously described (19), neonatal
Holstein dairy calves obtained from status level 4 herds enrolled in the Voluntary
Bovine Johne’s Control Program were purchased at 1 to 2 days of age and
housed in biosafety level 2 containment barns for the duration of the study.
Control calves were housed in a barn separate from the experimentally infected
animals. Calves were allowed to acclimate to their environment for 1 week prior
to being assigned to the following treatment groups: (i) control noninfected
group (n  4), (ii) oral group (n  4), (iii) oral/dexamethasone (oral/DXM)
group (n  4), (iv) i.p. group (n  4), and (v) oral/mucosal (oral/M) group (n 
3). Descriptions of the inoculum preparation and the route of inoculation are
provided in a previously published manuscript (19). Briefly, on day 0 of the study,
the oral and oral/DXM groups were fed milk replacer containing, on average,
1  1011 live M. avium subsp. paratuberculosis organisms of the low-passage
strain K-10 2 times per day for 14 consecutive days. However, the oral/DXM
group was administered 0.25 mg DXM/kg of body weight (Azium; 23 Schering
Corp., Kenilworth, NJ) intravenously (i.v.) for 3 days prior to the first bacterial
challenge and then administered the same dosage of DXM on days 28 and 56 of
the study. Intraperitoneal inoculation of calves was performed on days 0, 7, 14,
and 21 of the study by inoculation of 1 ml of M. avium subsp. paratuberculosis
(1011 bacteria) through a 3-mm incision in the right flank (19). The oral/M group
calves were inoculated on days 0, 7, and 14 of the study by being fed milk replacer
containing 2.6  1012 live M. avium subsp. paratuberculosis organisms obtained
by scraping the ileal mucosa from a clinically infected cow. The numbers of viable
M. avium subsp. paratuberculosis organisms in the inoculum preparations were
verified by performing serial 10-fold dilutions of the stocks in phosphate-buffered
saline (PBS), followed by plating onto Herrold’s egg yolk medium (HEYM;
Becton Dickinson, Sparks, MD) in duplicate and culturing for 12 weeks at 39°C.
Based upon the average recovery of M. avium subsp. paratuberculosis by culture,
approximate dosages of viable M. avium subsp. paratuberculosis organisms were
3.6  1012 for oral and oral/DXM group calves, 4  1011 for i.p. group calves, and
8  1012 for oral/M group calves during the study. All procedures performed on
the animals were approved by the Institutional Animal Care and Use Committee
of the National Animal Disease Center (NADC), Ames, IA. All calves, regard-
less of inoculation route, were confirmed to be infected by culture of intestinal
tissues and associated lymph nodes, as well as the spleen and liver, taken at
necropsy (19).
Blood collection and culture conditions. Blood was collected from the jugular
vein in 2 acid-citrate-dextrose (ACD; 1:10). For each animal, blood was col-
lected on 2 consecutive days prior to initiation of the study, followed by sampling
on days 7, 14, and 28 and monthly thereafter for 12 months. Peripheral blood
mononuclear cells (PBMCs) were isolated from the buffy coat fractions of blood.
PBMCs were resuspended in complete medium (RPMI 1640 [Gibco, Grand
Island, NY] with 10% fetal calf serum [Atlanta Biologics, Atlanta, GA], 100 U of
penicillin G sodium [Gibco] per ml, 100 g of streptomycin sulfate [Gibco] per
ml, 0.25 g of amphotericin B [Gibco] per ml, and 2 mM L-glutamine [Gibco]).
Cells were cultured at 2.0  106/ml in replicate 48-well flat-bottomed plates
(Corning Incorporated, Corning, NY) at 39°C in 5% CO2 in a humidified atmo-
sphere. Duplicate wells were set up for each animal for each in vitro treatment.
In vitro treatments consisted of no stimulation (NS; medium only), concanavalin
A (ConA) (10 g/ml; Sigma Chemical Co., St. Louis, MO), and M. avium subsp.
paratuberculosis whole-cell sonicate (MPS; 10 g/ml). Plates were incubated for
6 days, and cells were harvested for flow cytometric analyses.
Flow cytometric analysis. Briefly, culture plates were centrifuged at 1,500 rpm
for 5 min, and the supernatant was decanted. Cells were gently resuspended in
300 l of PBS (0.15 M, pH 7.4). In 96-well round-bottom plates (Corning
Incorporated), 50 l of the cell suspension was added to wells containing 50 l
of primary monoclonal antibody to B cells, CD5, CD25, and CD45RO (Table 1).
All wells received 10 g/ml of DAPI (4,6-diamidino-2-phenylindole; Sigma) to
differentiate live from dead cells and to allow gating on viable cells. Cells were
then incubated at 4°C for 30 min. After incubation, plates were centrifuged at
1,250 rpm for 2 min at 4°C, and the supernatant was decanted. One hundred
microliters of secondary antibody cocktail, consisting of fluorescein-conjugated
anti-mouse IgM (Southern Biotech, Birmingham, AL), R-phycoerythrin-conju-
gated goat F(ab)2 anti-mouse IgG2a (Southern Biotech), and peridinin chloro-
phyll protein complex-conjugated rat anti-mouse IgG1 (Becton Dickinson, San
Jose, CA), diluted 1:312, 1:625, and 1:42, respectively, in PBS with 1% fetal calf
serum and 0.04% sodium azide, was then added to designated wells, and plates
were centrifuged again at 1,250 rpm for 2 min at 4°C. The cells were then
suspended in 200 l of BD FacsLyse (BD Biosciences, San Jose, CA) for im-
mediate flow cytometric analysis. Samples were evaluated using 30,000 events
per sample in a FACScan flow cytometer with Cell Quest software (Becton
Dickinson). Analysis was conducted by gating on mononuclear cells, based on
forward and side scatter characteristics (FlowJo; Tree Star, Inc., San Carlos,
CA). The percentages of total B cells and CD25-, CD45RO-, and CD5-positive
cells within the B cell population were also determined. During flow cytometric
analysis, the CD5 subpopulation was further segregated into CD5bright and
CD5dim populations as previously reported for bovine B cells (18).
Immunoblotting of sera. Electrophoresis and immunoblot assays were per-
formed using previously reported procedures (3). Briefly, a whole-cell sonicate of
M. avium subsp. paratuberculosis (K-10 strain) was prepared by sonication of M.
avium subsp. paratuberculosis organisms (1  109/ml) in PBS at 25 W for 25 min
on ice (Tekmar sonic disturber; Tekmar, Lorton, VA), and the protein concen-
tration was determined. The MPS was diluted to a final concentration of 1 mg/ml
and then stored at 20°C. The reactivities of serum and plasma samples from
cattle against the whole-cell sonicate were assessed using a Mini-Protean II slot
blot device (Bio-Rad, Richmond, CA). Antigen was electrophoresed through
preparative 12% (wt/vol) polyacrylamide gels and transferred to nitrocellulose
filters. These filters were placed in a blocking solution consisting of phosphate-
buffered saline plus 0.1% Tween 20 and 2% (wt/vol) bovine serum albumin
(PBST-BSA). After being blocked, the filters were placed into the slot blot
device, and individual sera, diluted 1:200 in PBST-BSA, were added to indepen-
dent slots. After a 2-h incubation with gentle rocking, blots were washed three
times with PBST and incubated with horseradish peroxidase-conjugated anti-
goat IgG heavy and light chains (Vector Laboratories, Burlingame, CA) diluted
1:20,000 in PBST-BSA for 1.5 h. Blots were again washed three times with PBST
and were developed for chemiluminescence in SuperSignal detection reagent
(Thermo Scientific, Rockford, IL).
EvELISA. Surface antigens of M. avium subsp. paratuberculosis (strain Linda)
were extracted using 80% ethanol as previously described (8). Strain Linda, an
isolate from a human patient with Crohn’s disease (ATCC, Manassas, VA),
resulted in more sensitive detection of antibody in JD-positive sera than in strain
K-10 extracts (unpublished results). Briefly, M. avium subsp. paratuberculosis was
harvested at stationary phase and centrifuged at 4,500 rpm for 10 min, and the
pellet was resuspended in 80% ethanol to make 80 mg wet weight of M. avium
subsp. paratuberculosis/ml of ethanol solution. The suspension was then vortexed
for 30 s at room temperature, followed by centrifugation at 9,000 rpm for 10 min.
The supernatant was diluted by a factor of 80 with 80% ethanol and inoculated
into each well of 96-well plates (50 l/well) (PolySorp Nunc-Immuno 96-micro-
well plate; Nalge Nunc International, Rochester, NY). The plates were then
incubated with the cover removed overnight in a fume hood at room temperature
to allow the extracted antigens to adhere to the surfaces of the wells by evapo-
ration. Each well of the plate was then incubated with 200 l of buffer A at room
temperature for 1 h, washed twice with 100 l of PBST (10 mM phosphate-
buffered saline, pH 7.0, containing 0.5% Tween 80), and inoculated with 50 l of
sera, including M. avium subsp. paratuberculosis-positive and M. avium subsp.
paratuberculosis-negative control sera. Sera were diluted 1:100 with buffer A and
then incubated at room temperature for 1 h. After washing of the wells four
TABLE 1. Primary antibodies used in this studya
Antigen Antibodyclone Isotype
Working
MAb concn
(g/ml)b
Specificity
B lymphocyte BAQ155A IgG1 7 Total B cells
CD5 B29a IgG2a 7 Activation marker
CD25 CACT116A IgG1 15 IL-2 receptor
CACT108A IgG2a 15 IL-2 receptor
LCTB2A IgG3 15 IL-2 receptor
CD26 CACT114A IgG2b 15 Activation marker
CD45RO GC42A1 IgG1 10 Memory/activation marker
a Obtained from VMRD Inc. (Pullman, WA).
b Antibodies were diluted in PBS with 1% fetal calf serum and 0.04% sodium
azide.
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times with 100 l of PBST, each well was inoculated with 50 l of horseradish
peroxidase-labeled goat anti-bovine IgG(HL) polyclonal antibody (1:500 dilu-
tion; Jackson ImmunoResearch Laboratories, West Grove, PA) or with 50 l of
biotin-labeled goat anti-bovine IgG(HL) polyclonal antibody (1:500 dilution;
Jackson ImmunoResearch Laboratories) and then incubated at room tempera-
ture for 1 h. Plates were then incubated with horseradish peroxidase-labeled
streptavidin (50 l per well; 0.5 g/ml) (Pierce Biotechnology, Rockford, IL) at
room temperature for 1 h. After washing of the wells five times with 100 l of
PBST, ABTS (2,2-azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammo-
nium salt) tablets were used to develop color reactions according to the manu-
facturer’s instructions, and optical densities (ODs) at 415 nm were determined by
a microplate reader (model 680; Bio-Rad, Hercules, CA) at 2-min intervals for
16 min. Aliquots of the same serum samples were also tested using a commercial
enzyme-linked immunosorbent assay (ELISA) (Herdchek; Idexx, Westbrook,
ME) according to the manufacturer’s instructions. Samples were determined as
positive or negative based upon the sample-to-positive-control (S/P) ratio.
Briefly, serum samples from known M. avium subsp. paratuberculosis-positive and
-negative cows by prior screening were used as positive and negative controls in
each ELISA. S/P ratios were then calculated as follows: S/P ratio  (sample
serum OD  negative-control serum OD)/(positive-control serum OD  nega-
tive-control serum OD). S/P ratios for the ethanol vortex ELISA (EvELISA)
varied with the known positive and negative samples used in each test but
averaged 0.038 (mean  2 standard deviations [SD]) for the noninfected calves
in this study. The commercial test kit has an S/P ratio of 0.250, as the positive and
negative controls are standardized.
For all cell analyses, nonstimulated (medium control) cultures were included
to measure constitutive responses to infection and ConA-stimulated cultures
were included as positive controls to determine general cell reactivity. However,
our interest was primarily on antigen-specific recall responses after experimental
infection, so the ConA responses are not shown. In general, few differences in
ConA responses were noted between control noninfected animals and experi-
mentally infected calves.
Statistical analysis. The percentage of each cell population was analyzed by
using the PROC MIXED analysis of SAS (SAS PC Windows, version 9.1.3,
software). Values are reported as least-square means  standard errors of the
means (SEM) unless noted otherwise. When significant effects (P  0.05) owing
to treatment, day, or treatment-day interactions were detected, mean compari-
sons between the control group and infected treatment groups were conducted
by the Tukey-Kramer post hoc test. For clarity in presentation, symbols are used
in the figures to designate significant differences between control calves and
experimentally infected calves within each time point. Differences due to day
(time after infection) or treatment-day interactions are discussed within the text
and are not represented by symbols in the figures.
RESULTS
Tissue colonization after infectious challenge. The mode of
experimental M. avium subsp. paratuberculosis infection was
previously demonstrated to have an impact on the extent of
tissue colonization and lesion formation (19). Briefly, calves
that were orally inoculated with a clinical isolate of M. avium
subsp. paratuberculosis (oral/M group) had the largest number
of positive tissue sites (15/22 tissues), whereas i.p. group calves
had the smallest number of positive tissue sites (8.5/22 tissues).
Bacterial burdens within tissues were low across treatment
groups, except for one calf within the oral/M group that had
large numbers of M. avium subsp. paratuberculosis organisms.
Lesion formation within tissues was fairly unremarkable and
was greatest in oral/DXM group calves, followed by oral,
oral/M, and, lastly, i.p. group calves. No consistent pattern
between tissue infectivity or pathology and B cell responses
could be discerned for calves in the present study.
B cell responses in infected calves. Culturing PBMCs with
medium alone (NS) allowed us to discern differences in the
percentage of total B cells due to infection status (Fig. 1A).
Differences due to the mode of infection were not demon-
strated until 3 months of infection, with increases (P  0.05) in
B cells observed for oral and i.p. group calves. Thereafter, a
decline in B cells was noted throughout the remainder of the
study for all groups, yet i.p. group calves continued to demon-
strate elevated numbers of B cells compared to the noninfected
controls and other treatment groups. Interestingly, oral/DXM
group calves were the only group with smaller numbers of B
cells than the control calves, although this was significant (P 
0.05) only at 3 months. We also evaluated changes in B cell
populations in fresh, noncultured PBMCs to determine if the
mode of infection would affect B cell numbers, but treatment
differences mirrored results for the NS cultured PBMCs, so
those data are not shown. Upon stimulation of PBMCs with
antigen (MPS), patterns of B cell numbers were similar to that
observed for NS cultures, although at some time points the
results were more definitive (Fig. 1B). The percentage of B
cells in MPS-stimulated cultures increased (P  0.05) for oral,
oral/M, and i.p. group calves between 1 and 3 months, paral-
leling what was observed for nonstimulated cultures (Fig. 1A
and B). Further increases (P  0.05) in B cells were noted for
oral/M group calves at 6 months, while in other treatment
groups, B cell numbers had begun to decline by 6 months, with
further reductions noted at 9 and 12 months. The percentages
of antigen-specific B cells at 9 and 12 months were higher (P 
0.05) for i.p. group calves than for control noninfected calves
(Fig. 1B), an effect that had been noted for nonstimulated
PBMCs (Fig. 1A). Interestingly, for both the control nonin-
fected calves and oral/DXM group calves, percentages of B
cells were similar to those for other treatment groups at 1
month but had declined by 6 months and remained lower than
those for the other treatment groups for the rest of the study,
indicating that dexamethasone pretreatment disrupted the
ability of calves to develop B cell responses to M. avium subsp.
paratuberculosis infection at levels comparable to those for
calves in other infection groups.
Inoculating the calves with a clinical isolate of M. avium
subsp. paratuberculosis (oral/M group) resulted in an increase
(P  0.01) in the CD5dim B cell subpopulation at 9 and 12
months in both nonstimulated and MPS-stimulated cultures
(Fig. 2A and B). At 12 months postinfection, the percentage of
CD5dim B cells in nonstimulated PBMCs was significantly (P 
0.05) higher for oral/M and oral/DXM group calves than for
the control noninfected calves (Fig. 2A). A significant increase
(P  0.01) was also noted for MPS-stimulated PBMCs isolated
from oral/M, oral/DXM, and i.p. group calves at 12 months.
The percentage of CD5dim B cells remained fairly consistent
throughout the study for both nonstimulated and MPS-stimu-
lated PBMCs isolated from control calves. Oral/DXM group
calves had larger numbers of CD5bright B cells in nonstimu-
lated PBMC cultures than did control calves in the early
months of the study (significant [P  0.05] at 1 month) and
tended to have higher levels than the other infection groups for
most time points (Fig. 3A). The exception was a marked (P 
0.05) increase in the CD5bright B cell subpopulation noted for
oral/M group calves between 3 and 9 months of the study,
resulting in higher (P  0.05) expression levels than those for
the other treatment groups at 9 months. The addition of MPS
to unfractionated PBMCs resulted in similar trends shortly
after experimental infection, with increases (P  0.05) in
CD5bright B cells noted for oral/DXM group calves at 6, 9, and
12 months and for oral/M calves at 9 and 12 months compared
to time zero. Increases (P  0.05) in CD5bright B cells were also
VOL. 18, 2011 B CELL RESPONSES TO PARATUBERCULOSIS 1141
  
noted for oral group and control noninfected calves at 12
months postinfection compared to the 3-month time point
(Fig. 3B). Comparison of the ex vivo stimulation of unfraction-
ated PBMCs with medium alone (nonstimulated) and MPS at
1 and 12 months suggested that additional stimulation with M.
avium subsp. paratuberculosis antigen resulted in a shift in the
phenotype of the CD5-positive cells for some treatment groups
at 12 months (Fig. 4A and B). At 1 month postinfection, there
was little discernible effect due to stimulation of cells with MPS
(Fig. 4A), but after 12 months of infection, a significant shift
(P  0.05) to increased numbers of CD5bright B cells was
observed upon the addition of MPS to PBMC cultures for oral
and oral/M group calves (Fig. 4B). Overall time effects be-
tween 1 and 12 months of infection demonstrated significant
increases (P  0.05) in CD5bright expression on B cells in
MPS-stimulated cultures for control, oral, and oral/M group
calves.
Experimental infection of calves resulted in significant (P 
0.05) increases in the percentage of CD25 B cells in non-
stimulated PBMCs from oral, i.p., and oral/DXM group calves,
but not oral/M group calves, compared to control calves at 1
month postinfection (Fig. 5A). By 6 months, these trends con-
tinued but were not significant. However, by 12 months postin-
fection, CD25 B cells had increased for oral/M group calves,
resulting in larger (P  0.05) numbers for oral/DXM and
oral/M group calves than for control calves at the termination
of the study. Although CD25 B cells decreased for oral and i.p.
group calves at this time point, their levels still tended to be
higher (P  0.10) for oral group calves than for the controls.
Similar patterns of CD25 expression were noted on B cells
among MPS-stimulated PBMCs at 1, 6, and 12 months of the
study (Fig. 5B), but increases in expression for oral and i.p.
group calves were more significant at 6 months. Between 1 and
12 months, significant increases (P  0.05) in the percentage of
CD25 B cells were observed for oral/M group calves, regard-
less of ex vivo stimulation of PBMCs.
The expression of CD45RO on B cells in MPS-stimulated
PBMCs was upregulated in oral/DXM group calves (P  0.01)
FIG. 1. Percentages of B cells from PBMCs isolated from control noninfected calves (}) and calves infected with Mycobacterium avium subsp.
paratuberculosis by the following methods: oral (f), intraperitoneal (Œ), oral with dexamethasone administration (E), and oral with mucosal
scrapings from a cow with clinical disease (). Data are for a 12-month study with nonstimulated PBMCs (A) and PBMCs stimulated with a
whole-cell sonicate of Mycobacterium avium subsp. paratuberculosis (MPS) (B). Data are expressed as means  SEM. Significant differences
between control and infection groups for given time points are represented by asterisks (, P  0.01; , P  0.05).
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and tended to be higher in oral group calves (P  0.10) at 3
months postinfection than in control calves (Fig. 6). However,
by 6 months postinfection, significant (P  0.01) upregulation
of CD45RO B cells was observed for all experimentally in-
fected calves, except for oral/M group calves (due to high
variability). At 12 months postinfection, this subpopulation of
B cells was significantly greater for oral/DXM and oral/M
group calves, averaging 57.6 and 55.2%, respectively, com-
pared to 29.1% of the total B cell population for control calves
at 12 months (Fig. 6). Similar trends in CD45RO expression on
B cells were observed for nonstimulated PBMCs (Fig. 6A).
Serum antibody responses in infected calves. Immunoblot
analysis was performed with sera from calves across all time
points of the study (days 3, 2, 7, 14, and 21 and months 1
to 12). A whole-cell sonicate preparation of M. avium subsp.
paratuberculosis strain K-10 was used as the antigen to assess
the presence of serum antibodies. Sample blots for a represen-
tative calf from each treatment group are shown in Fig. 7.
Banding patterns varied with treatment group, but major
bands were apparent at 25, 42, and 50 kDa among the infection
groups. Sera from control noninfected calves were consistently
nonreactive on blots (Fig. 7A). Little immunoreactivity was
observed for calves in the oral treatment group, with a major
band apparent at approximately 42 kDa (Fig. 7B). Calves that
were infected i.p. had the most robust responses, with numer-
ous bands observed, including the 42-kDa band noted for oral
group calves. Immunoreactivity was particularly robust be-
tween 1 and 6 months of infection, but strong reactivity was still
discernible, with banding at 37, 42, 50, and 75 kDa, through the
termination of the study (Fig. 7C). Another band of interest
appeared at 25 kDa and was apparent for the majority of time
points. Treatment of calves with dexamethasone prior to oral
inoculation resulted in a delayed appearance of antibody, with
bands appearing within 3 months and continuing through the
12-month study (Fig. 7D). This effect was observed for all 4
calves in the oral/DXM treatment group (data not shown),
with 42-, 50-, and 75-kDa bands demonstrating the most con-
sistency, although strong banding at 25 kDa was also noted in
the latter part of the study. Surprisingly, the immunoblots for
oral/M group calves demonstrated an early antibody response,
FIG. 2. Percentages of CD5dim B cells from PBMCs isolated from control noninfected calves (}) and calves infected with Mycobacterium avium
subsp. paratuberculosis by the following methods: oral (f), intraperitoneal (Œ), oral with dexamethasone administration (E), and oral with mucosal
scrapings from a cow with clinical disease (). Data are for a 12-month study with nonstimulated PBMCs (A) and PBMCs stimulated with MPS
(B). Data are expressed as means  SEM. Significant differences between control and infection groups for given time points are represented by
asterisks (, P  0.01; , P  0.05).
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with banding apparent at 25 and 50 kDa within 7 days of
infection. Banding was markedly weaker after 5 months of
infection but was still detectable at 42 and 50 kDa (Fig. 7E).
Further testing for M. avium subsp. paratuberculosis-specific
antibody by the EvELISA method demonstrated the presence
of antibody (determined by S/P ratio) only in the sera from i.p.
inoculated calves (Fig. 8). Values for a control calf were plot-
ted to demonstrate differences obtained between i.p. group
calves and those from the other treatment groups. No antibody
was detected by this method in any of the other treatment
groups. As noted on the scattergram plot in Fig. 8, antibody
was detected for 3 of 4 i.p. group calves (}, f, and Œ), ranging
from 2 to 7 months postinoculation. Little antibody was de-
tected by this method in the other i.p. group calf (). Use of
a commercial kit for the detection of M. avium subsp. paratu-
berculosis antibodies in the sera of experimentally infected
calves was less sensitive, with positive S/P values of 0.417,
0.349, and 0.347 observed for only 1 i.p. group calf, at 7, 8, and
9 months postinfection, respectively (data not shown). Reac-
tivity was observed in 2 additional i.p. group calves, but the
level remained below the threshold of positive responses (S/P
ratio of 0.250) outlined in the manufacturer’s instructions. In-
terestingly, even though positive reactivity was attained to
some degree for the same 3 i.p. group calves in both assays, the
EvELISA detected antibody in the sera several months earlier
than the commercial kit did.
DISCUSSION
The progression of paratuberculosis from an asymptomatic
subclinical state to one of clinical disease, as defined by signs of
severe diarrhea and emaciation, coincides with a shift from
Th1- to Th2-mediated immunity (16). The production of the
Th2 regulatory cytokines interleukin-4 (IL-4), IL-5, and IL-10
supports a humoral immune response characterized by the
proliferation of B cells, immunoglobulin secretion, and atten-
uation of Th1-mediated responses. The role that B cells may
play in mycobacterial infections is not well understood, nor has
it been addressed adequately. B cells are an essential compo-
nent of adaptive immunity and are most noted for their ability
to secrete antibodies that bind to pathogens and facilitate their
uptake by phagocytic cells. B cells can also develop into mem-
ory cells, promoting an anamnestic response to antigens upon
secondary exposure. However, B cells are antigen-presenting
FIG. 3. Percentages of CD5bright B cells from PBMCs isolated from control noninfected calves (}) and calves infected with Mycobacterium
avium subsp. paratuberculosis by the following methods: oral (f), intraperitoneal (Œ), oral with dexamethasone administration (E), and oral with
mucosal scrapings from a cow with clinical disease (). Data are for a 12-month study with nonstimulated PBMCs (A) and PBMCs stimulated with
MPS (B). Data are expressed as means  SEM. Significant differences between control and infection groups for given time points are represented
by asterisks (, P  0.01; , P  0.05).
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cells as well and play a role in the activation of CD4 Th2 cells.
Although it has not been explored fully, the decrease in CD4
Th1-mediated function noted in the later stages of paratuber-
culosis may be associated closely with an increase in B cell
activity (10).
An observation made previously by our group suggested that
a shift in the percentage of B cells in the peripheral blood
occurred with M. avium subsp. paratuberculosis infection, with
increasing numbers in naturally infected cows demonstrating
clinical signs of paratuberculosis compared to those in subclin-
ically infected cows or healthy controls (19). Interestingly, the
B cells isolated from cows with clinical disease were unrespon-
sive to an M. avium subsp. paratuberculosis antigen prepara-
tion, whereas a normal proliferative response to the mitogen
concanavalin A was observed. These observations were aligned
with typical antemortem signs of clinical disease such as diar-
rhea and weight loss, concomitant with heavy shedding of M.
avium subsp. paratuberculosis in the feces and a high serum
antibody titer observed in the laboratory. Other studies have
also suggested a link between B cell function and disease state.
B cell knockout mice demonstrated delayed dissemination of
M. tuberculosis from the lungs to the spleen and liver and
delayed development of pulmonary lesions after challenge (5).
A more recent study suggested that B cell involvement may not
be so clear-cut, as infection of RAG/ mice deficient in both
B and T cells with M. tuberculosis did not affect dissemination
into the spleen or the lungs or granuloma formation in the
lungs (7). These observations suggest that B cell-T cell inter-
actions are an integral component of the host response to
mycobacterial infections in general and that B cells may play a
significant role in regulating the pathogenesis of infection.
The present study was designed to evaluate host responses
to different routes of experimental infection, including the
evolution of B cell responses over a specific period of infection.
Although calves in this study remained asymptomatic and sub-
clinically infected during the 12-month term, as determined by
FIG. 4. Comparison of in vitro stimulation with medium control (NS) and a whole-cell sonicate of Mycobacterium avium subsp. paratuberculosis
(MPS) on the percentage of CD5bright B cells from PBMCs isolated from calves at 1 month of infection (A) and 12 months of infection (B). Data
are expressed as means  SEM. Significant differences between NS and MPS-stimulated PBMCs within a treatment group are represented by
asterisks (, P  0.01; , P  0.05).
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recovery of viable M. avium subsp. paratuberculosis organisms
from their tissues, an induction of total B cells and B cell
subpopulations was observed, and this varied with the mode of
experimental infection.
Although all experimentally inoculated calves in the present
study would be considered subclinically infected, the oral/M
group calves demonstrated the most significant degree of in-
fection, as ascertained by recovery of M. avium subsp. paratu-
berculosis from tissues by culture or by PCR (19). Interestingly,
the oral/M group calves also had increasing percentages of
CD5, CD25, and CD45RO subpopulations at several time
points throughout the study, suggesting that an increase in
colonization of tissues may signal a concomitant shift to acti-
vated B cell subpopulations. Calves in the oral/DXM treatment
group also showed significant shifts in the proportions of these
B cell populations by 12 months of infection, correlating with
the larger number of lesions noted in these calves (19). It is
unknown if the upregulation of CD45RO on B cells in the
oral/M and oral/DXM group calves is suggestive of a relation-
ship between localized invasion and inflammation of the target
tissues, but an upregulation of CD45RO expression on periph-
eral blood and lamina propria B cells has been observed in
humans diagnosed with inflammatory bowel diseases such as
Crohn’s disease and ulcerative colitis (22, 23).
Similarly, increased expression of CD25 (IL-2 receptor) on
B cells has been noted in rheumatic and inflammatory bowel
diseases in humans and has also been associated with pathogen
exposure in cattle (2, 9, 12, 22). CD25 B cells constitute a
more mature phenotype and are more efficient at antigen pre-
sentation but may secrete less immunoglobulin (1). Interest-
ingly, neonatal calves vaccinated with either ovalbumin or M.
bovis bacillus Calmette-Guérin (BCG) demonstrated increased
CD25 B cells in the superficial cervical lymph node cell pop-
ulation upon restimulation of cells with antigen (9). This effect
was not associated with antibody secretion. Furthermore, 4.5
years after exposure of neonatal calves to bovine leukemia
virus, cultured peripheral blood mononuclear cells demon-
strated an increased expression of CD25 on B cells that was
coincident with increased CD25 expression on CD4 and CD8
T cells (12). It is not clear whether CD25 expression on B cells
FIG. 5. Percentages of CD25 B cells from PBMCs isolated from control noninfected calves and calves infected with Mycobacterium avium
subsp. paratuberculosis by the following methods: oral, intraperitoneal, oral with dexamethasone administration, and oral with mucosal scrapings
from a cow with clinical disease. Data are for a 12-month study with nonstimulated PBMCs (A) and PBMCs stimulated with MPS (B). Data
are expressed as means  SEM. Significant differences between the control and infection groups for given time points are represented by
asterisks (, P  0.01; , P  0.05).
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is a positive indicator of host immunity, as it has been surmised
that it may enhance interactions between B and T cell popu-
lations, whereas for human beings it has been suggested that
CD25 B cells are a unique subset of memory B cells that may
play a role in the pathogenesis of autoimmune disorders (2).
The implication that the CD25 B cell phenotype does not
play a major role in immunoglobulin secretion appears to cor-
roborate results within the present study. Immunoblot and
ELISA analyses demonstrated a higher degree of M. avium
subsp. paratuberculosis-specific antibody in i.p. group calves,
yet CD25 expression on B cells from these calves was not
sustained throughout the study, resulting in a marked decline
after 6 months of infection. This contrasted sharply with the
increased expression of CD25 observed for calves inoculated
via the oral route, regardless of which M. avium subsp. para-
tuberculosis isolate was given to calves or if the calves were
administered DXM prior to inoculation. This suggests that the
direct inoculation of M. avium subsp. paratuberculosis into the
peritoneal cavity may have activated a different subset of B
cells from those observed in the orally inoculated calves.
B cell populations may be segregated into subclasses by
using activation markers such as CD5 to separate them into
B-1 (CD5) and B-2 (CD5) classes. B-2 cells represent the
normal circulating B cell population (13). The B-1 population
can be subdivided further into B-1a and B-1b subclasses. Al-
though both subclasses have the CD5 phenotype, B-1b cells
lack the surface receptor for CD5 (24). Recent work described
the expansion of a CD5bright subpopulation of B cells in the
peripheral blood of cattle subclinically infected with M. avium
subsp. paratuberculosis that likely represents the B-1a popula-
tion (18). This is significant in that it suggests that a shift in B
cell subpopulations takes place during infection and may di-
rectly or indirectly affect pathogenesis induced by inflamma-
tory T cells. Haas and Estes (11) demonstrated that bovine
CD5 B cells could be activated to express CD5 by cross-
linking the B cell receptor but not upon ligation with CD40. It
would be interesting to explore this application in M. avium
subsp. paratuberculosis-infected cattle to determine if CD5 ex-
pression on B cells relates to a T cell-independent mechanism.
The appearance of M. avium subsp. paratuberculosis-specific
antibody was not expected in the present study due to the
limited period of infection (12 months). M. avium subsp. para-
tuberculosis-specific antibody is most frequently associated with
the later stages of infection and clinical disease, although an-
FIG. 6. Percentages of CD45RO B cells from PBMCs isolated from control noninfected calves and calves infected with Mycobacterium avium
subsp. paratuberculosis by the following methods: oral, intraperitoneal, oral with dexamethasone administration, and oral with mucosal scrapings
from a cow with clinical disease. The data are for a 12-month study with nonstimulated PBMCs (A) and PBMCs stimulated with MPS (B). Data
are expressed as means  SEM. Significant differences between the control and infection groups for given time points are represented by asterisks
(, P  0.01; , P  0.05).
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tibody is detectable in asymptomatic infection as well (19a).
Immunoblot analysis demonstrated that the reactivity of calf
sera was highest and most consistent in i.p. group calves, al-
though transient antibody was apparent in oral treatment
groups as well. The EvELISA results were consistent with the
immunoblot analyses, with positive responses noted only for
i.p. group calves. The EvELISA protocol utilizes a novel
method of antigen preparation and has previously demon-
FIG. 7. Immunoblotting of serum from a representative calf for each treatment group. (A) Control; (B) oral; (C) intraperitoneal; (D) oral with
dexamethasone; (E) oral with mucosal scrapings from a cow with clinical disease. Sera were blotted against a whole-cell sonicate preparation of
Mycobacterium avium subsp. paratuberculosis strain K-10. Lanes 1 to 17, days 3, 2, 7, 14, and 21 and months 1 through 12, respectively.
FIG. 8. Scattergram of EvELISA S/P ratios demonstrating antibody reactivity of sera from 4 calves in the i.p. treatment group compared to
baseline values for one control noninfected calf. Values over the time course of the study are shown, and each symbol represents a single calf across
time.
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strated an improved sensitivity of detection compared to more
traditional ELISAs for paratuberculosis (8). A mechanism to
explain why i.p. group calves produced more M. avium subsp.
paratuberculosis-specific antibody is not readily available, but
the appearance and maintenance of antibody responses for i.p.
group calves aligned with the higher percentage of total B cells
during the 12-month study. It is possible that inoculation of M.
avium subsp. paratuberculosis directly into the peritoneum al-
lowed for a more rapid uptake by antigen-presenting cells in
the draining lymph nodes, thereby invoking a more robust and
protracted antibody response. No other B cell activation mark-
ers (CD5, CD25, or CD45RO) demonstrated any alignment
with antibody responses.
In conclusion, it is apparent that M. avium subsp. paratuber-
culosis infection of neonatal calves, regardless of the route of
experimental inoculation, invokes a strong activation of B cells.
The temporal expression of CD5, CD25, and CD45RO mark-
ers on B cells suggests that the route of infection and the M.
avium subsp. paratuberculosis isolate used to infect the calves
have significant effects on the period of upregulation of these
B cell markers. Presumably, this correlates with the period of
sustainability of activated B cells in the peripheral circulation
and could be a critical indicator of how neonatal calves re-
spond to an enteric pathogen such as M. avium subsp. paratu-
berculosis in a natural infection. Further work needs to be
conducted to elucidate the role that B cells play in host re-
sponses to M. avium subsp. paratuberculosis infection, particu-
larly in regard to their interaction with T cells and how this
either leads to or averts pathogenesis.
ACKNOWLEDGMENTS
We thank Bruce Pesch, Trudy Tatum, Tonia McNunn, and Megan
Parlett for their excellent technical assistance, as well as Paul Amund-
son and Jerri Grove for their excellent care of the animals in this study.
This study was supported by a USDA-NRICAP (Johne’s Disease
Integrated Program) grant.
REFERENCES
1. Amu, S., A. Tarkowski, T. Dörner, M. Bokarewa, and M. Brisslert. 2006. The
human immunomodulatory CD25 B cell population belongs to the mem-
ory B cell pool. Scand. J. Immunol. 66:77–86.
2. Amu, S., K. Stromberg, M. Bokarewa, A. Tarkowski, and M. Brisslert. 2007.
CD25-expressing B-lymphocytes in rheumatics diseases. Scand. J. Immunol.
64:182–191.
3. Bannantine, J. P., and J. R. Stabel. 2000. HspX is present within Mycobac-
terium paratuberculosis-infected macrophages and is recognized by sera from
some infected cattle. Vet. Microbiol. 76:343–358.
4. Bondada, S., G. Bikah, D. A. Robertson, and G. Sen. 2000. Role of CD5 in
growth regulation of B-1 cells. Curr. Top. Microbiol. Immunol. 252:141–149.
5. Bosio, C. M., D. Gardner, and K. L. Elkins. 2000. Infection of B cell-deficient
mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay
in dissemination and development of lung pathology. J. Immunol. 164:6417–
6425.
6. Brisslert, M., et al. 2005. Phenotypic and functional characterization of
human CD25 B cells. Immunology 117:548–557.
7. Chackerian, A. A., J. M. Alt, T. V. Perera, C. C. Dascher, and S. M. Behar.
2002. Dissemination of Mycobacterium tuberculosis is influenced by host
factors and precedes the initiation of T-cell immunity. Infect. Immun. 70:
4501–4509.
8. Eda, S., et al. 2006. A highly sensitive and subspecies-specific surface antigen
enzyme-linked immunosorbent assay for diagnosis of Johne’s disease. Clin.
Vaccine Immunol. 13:837–844.
9. Foote, M. R., B. J. Nonnecke, D. C. Beitz, and W. R. Waters. 2007. Antigen-
specific B-cell responses by neonatal calves after early vaccination. J. Dairy
Sci. 90:5208–5217.
10. Gillian, S., R. O’Brien, A. D. Hughes, and J. F. T. Griffin. 2010. Identification
of immune parameters to differentiate disease states among sheep infected
with Mycobacterium avium subsp. paratuberculosis. Clin. Vaccine Immunol.
17:108–117.
11. Haas, K. M., and D. M. Estes. 2000. Activation of bovine B cells via surface
immunoglobulin M cross-linking or CD40 ligation results in different B-cell
phenotypes. Immunology 99:272–278.
12. Isaacson, J. A., K. P. Flaming, and J. A. Roth. 1998. Increased MHC class II
and CD25 expression on lymphocytes in the absence of persistent lympho-
cytosis in cattle experimentally infected with bovine leukemia virus. Vet.
Immunol. Immunopathol. 64:235–248.
13. Le Pottier, L., V. Devauchelle, J. O. Pers, C. Jamin, and P. Youinou. 2007.
The mosaic of B-cell subsets (with special emphasis on primary Sjögren’s
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